



Novel and Personalized Treatment Concepts in Gynecologic Cancer

Guest Editors:

Dr. Stephan Polterauer

Department of Obstetrics and
Gynecology, Comprehensive
Cancer Center-Gynecologic
Cancer Unit, Medical University of
Vienna, 1090 Vienna, Austria

Dr. Christoph Grimm

Division of General Gynaecology
and Gynaecological Oncology,
Vienna General Hospital, Medical
University of Vienna, 1090 Vienna,
Austria

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

The field of gynecologic oncology has evolved greatly within the last years. The introduction of molecular analysis has changed the way we classify endometrial and epithelial ovarian cancers. Moreover, surgical treatment concepts have developed due to the introduction of the sentinel lymph node technique, allowing us to spare patients from unnecessary morbidities. Finally, predictive biomarkers such as BRCA mutations, homologous recombination deficiency, and microsatellite instability have revolutionized the treatment of a variety of gynecologic malignancies.

In the precision medicine era, the further understanding of cancer genomics and the identification of predictive biomarkers are essential to achieve better health outcomes for women with gynecologic cancer.

In this Special Issue, we aim to cover highly innovative findings and concepts within the field of gynecologic oncology, ranging from diagnostics to therapeutic approaches, that could improve the way we diagnose, classify, and/or treat gynecologic malignancies. A special focus will be precision medicine using molecular approaches and targeted treatments including Immunotherapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA

2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)